Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment
Modern Pathology · 2023
DOI: 10.1016/j.modpat.2023.100332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Andrea Gillis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Somatostatin receptor type 2 (SSTR2) and thyroid-stimulating hormone receptor (TSHR) display variable expression in primary thyroid tumors and have been implicated as theranostic targets. This study was designed to explore the differential expression of SSTR2 and TSHR in oncocytic (Hurthle cell) carcinoma (OC) vs oncocytic adenoma (OA). We performed a retrospective review for oncocytic neoplasms treated at our institution from 2012 to 2019. Formalin-fixed paraffin-embedded tissue blocks were used for tissue microarray construction. Tissue microarray blocks were cut into 5-μm sections and stained with anti-SSTR2 and anti-TSHR antibodies. Immunostains were analyzed by 3 independent pathologists. χ2 and logistic regression analysis were used to analyze clinical and pathologic variables. Sixty-seven specimens were analyzed with 15 OA and 52 OC. The mean age was 57 years, 61.2% were women, and 70% were White. SSTR2 positivity was noted in 2 OA (13%) and 15 OC (28%; 10 primary, 4 recurrent, and 1 metastatic) (P = .22). TSHR positivity was noted in 11 OA (73%) and 32 OC (62%; 31 primary and 1 metastatic) (P = .40). Those who presented with or developed clinical recurrence/metastasis were more likely to be SSTR2-positive (50% vs 21%; P = .04) and TSHR-negative (64.3% vs 28.9%; P = .02) than primary OC patients. Widely invasive OC was more likely to be SSTR2-positive compared to all other OC subtypes (minimally invasive and angioinvasive) (P = .003). For all patients with OC, TSHR positivity was inversely correlated with SSTR2 positivity (odds ratio, 0.12; CI, 0.03-0.43; P = .006). This relationship was not seen in the patients with OA (odds ratio, 0.30; CI, 0.01-9.14; P = .440). Our results show that recurrent/metastatic OC was more likely to be SSTR2-positive and TSHR-negative than primary OC. Patients with OC displayed a significant inverse relationship between SSTR2 and TSHR expression that was not seen in patients with OA. This may be a key relationship that can be used to prognosticate and treat OCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
- Department of Medical Genetics, University of Wisconsin, Madison, Wisconsin.
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconin.
- Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: rjsztul@uabmc.edu.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: dmlin@uab.edu.
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- University of Alabama
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Gillis, A., Zheng-Pywell, R., McLeod, C., Wang, D., Ness, J. M., Guenter, R., Whitt, J., Prolla, T. A., Chen, H., Gonzalez, M. L., Rose, B., Lloyd, R. V., Jaskula-Sztul, R., & Lin, D. (2023). Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100332
Vancouver
Gillis A, Zheng-Pywell R, McLeod C, Wang D, Ness JM, Guenter R, et al. Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100332
BibTeX
@article{Gillis2023,
author = {Gillis, Andrea and Zheng-Pywell, Rui and McLeod, Chandler and Wang, Dezhi and Ness, John M and Guenter, Rachael and Whitt, Jason and Prolla, Tomas A and Chen, Herbert and Gonzalez, Manuel Lora and Rose, Bart and Lloyd, Ricardo V and Jaskula-Sztul, Renata and Lin, Diana},
title = {Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment},
journal = {Modern Pathology},
year = {2023},
doi = {10.1016/j.modpat.2023.100332}
}
EUVIMED